New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:47 EDTSGYPSynergy Pharmaceuticals announces extension for Q3 10-Q filing due to hurricane
Synergy Pharmaceuticals announced that, in accordance with applicable rules issued by the United States Securities and Exchange Commission, it will delay, for a short period, the filing of its quarterly Report on Form 10-Q for the three and nine months ended September 30, 2012. The company's normal process for compilation and review of its financial statements was delayed due to the company's accounting personnel not being able to travel to the company's headquarters and not being able to access the company's accounting records due to the effects of Hurricane Sandy.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
17:18 EDTSGYPSynergy Pharmaceuticals files $250M mixed securities shelf
Subscribe for More Information
June 24, 2015
05:59 EDTSGYPStocks with implied volatility below IV index mean; SGYP WMB
Subscribe for More Information
June 23, 2015
10:30 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information
09:14 EDTSGYPOn The Fly: Pre-market Movers
Subscribe for More Information
06:36 EDTSGYPSynergy Pharmaceuticals volatility elevated
Subscribe for More Information
06:02 EDTSGYPSynergy Pharma begins second of two Phase 3 clinical trials of plecanatide
Synergy Pharmaceuticals announced the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses, taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation, or IBS-C. The phase 3 IBS-C program includes two randomized, 12-week, double-blind, placebo-controlled pivotal trials conducted in the U.S. and each trial is expected to enroll approximately 1050 adult patients with IBS-C.
June 22, 2015
15:41 EDTSGYPSynergy Pharmaceuticals volatility elevated on sharp rally
Synergy Pharmaceuticals July is at 134, October is at 95; compared to its 52-week range of 72 to 158; suggesting large near term price move movement.
10:21 EDTSGYPOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use